Product Suite &
Pharmaceutical Pipeline

Pharmaceutical Pipeline

We are engaged in the development of novel therapeutics to address unmet medical needs in infectious disease and dermatology.

FDA Approval Process

Stage 1 – Discovery

Stage 2 – Manufacture

Stage 3 – Toxicity Trials

Stage 4 – Human Clinical Trials

Stage 5 – FDA Approval

Complete
Planned
Onychomycosis
Discovery
Manufacture
Toxicity Trials
Human Clinical Trials
FDA Approval
Infection/Eczema
Decolonization
Viral Conjuctivitis
Complete
Planned
Onychomycosis
Status: Stage 3 - Toxicity Trials
Infection/Eczema
Status: Stage 3 - Toxicity Trials
Decolonization
Status: Stage 3 - Toxicity Trials
Viral Conjuctivitis
Status: Stage 3 - Toxicity Trials

Pharmaceutical Pipeline

We are engaged in the development of novel therapeutics to address unmet medical needs in infectious disease and dermatology.

Onychomycosis
Discovery
Manufacture
Toxicity
Trials
Human Clinical
Trials
FDA
Approval
Infection/Eczema
Decolonization
Viral Conjuctivitis
Complete
Planned

Pharmaceutical Pipeline

We are engaged in the development of novel therapeutics to address unmet medical needs in infectious disease and dermatology.

*Lead candidate
**Orphan candidate
***CDC Emerging Threat

Bacterial Skin Infection*
Completed Pre-IND Meeting and CMC
Onychomycosis*
Completed Pre-IND Meeting and CMC
Intranasal COVID-19
Completed Phase 2B-OUS Approval in Process
Eczema
Phase 2B Ready
Herpes Zoster Ophthalmicus (HZO)**
Completed Animal Model
Basal Cell Carcinoma
Completed Animal Model
Intranasal Candida Auris***
Completed Animal Model

Product Suite

Market-ready assets include management tools for advanced wound care and dermatitis. Pipeline assets include FleX™ Antimicrobial, an antimicrobial regenerative collagen powder, as well as Xeal® Silicone, a non-adherent, antimicrobial silicone dressing.

Hexagen® Antimicrobial
FDA Cleared
Xeal® Antimicrobial Wound Dressing
FDA Cleared
AtopX™ Eczema Management Tool
FDA Cleared
FleX™ Antimicrobial Collagen Matrix
510k Submitted
Xeal® Non-Stick Antimicrobial Gauze
In Development
X-Fill™ Hemostat
In Development
Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX